Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK; Oxford Transplant Centre, Churchill Hospital, Oxford, UK.
Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK.
Trends Immunol. 2022 Jan;43(1):8-21. doi: 10.1016/j.it.2021.11.001. Epub 2021 Nov 26.
Organ transplantation is a modern medical success story. However, since its inception it has been limited by the need for pharmacological immunosuppression. Regulatory cellular therapies offer an attractive solution to these challenges by controlling transplant alloresponses through multiple parallel suppressive mechanisms. A number of cell types have seen an accelerated development into human trials and are now on the threshold of a long-awaited breakthrough in personalized transplant therapeutics. Here we assess recent developments with a focus on the most likely candidates, some of which have already facilitated successful immunosuppression withdrawal in early clinical trials. We propose that this may constitute a promising approach in clinical transplantation but also evaluate outstanding issues in the field, providing cause for cautious optimism.
器官移植是现代医学的成功案例。然而，自诞生以来，它一直受到药物免疫抑制的限制。调节性细胞疗法通过多种平行抑制机制控制移植同种反应，为应对这些挑战提供了一个有吸引力的解决方案。许多细胞类型的发展速度加快，已经进入人体试验阶段，现在有望在个性化移植治疗方面取得突破性进展。在这里，我们评估了最近的进展，重点关注最有希望的候选者，其中一些候选者已经在早期临床试验中成功实现了免疫抑制的撤药。我们认为，这可能是临床移植中一种很有前途的方法，但也评估了该领域的突出问题，谨慎乐观地认为这可能是一种很有前途的方法。
